Kotaro Yuge

Dr. Kotaro Yuge


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
YOYasuyoshi Oka
Yasuyoshi Oka
MHMotoharu Hamada
Motoharu Hamada
YNYuka Nakazawa
Yuka Nakazawa
HMHideki Muramatsu
Hideki Muramatsu
YOYusuke Okuno
Yusuke Okuno
TOTomoo Ogi
Tomoo Ogi
Rs671 in the aldehyde dehydrogenase 2 gene (ALDH2) is the cause of Asian alcohol flushing response after drinking. ALDH2 detoxifies endogenous aldehydes, which are the major source of DNA damage repaired by the Fanconi anemia pathway. Here, we show that the rs671 defective allele in combination with mutations in the alcohol dehydrogenase 5 gene, which encodes formaldehyde dehydrogenase (ADH5FDH), causes a previously unidentified disorder, AMeD (aplastic anemia, mental retardation, and dwarfism) syndrome. Cellular studies revealed that a decrease in the formaldehyde tolerance underlies a loss of differentiation and proliferation capacity of hematopoietic stem cells. Moreover, Adh5−/−Aldh2E506K/E506K double-deficient mice recapitulated key clinical features of AMeDS, showing short life span, dwarfism, and hematopoietic failure. Collectively, our results suggest that the combined deficiency of formaldehyde clearance mechanisms leads to the complex clinical features due to overload of formaldehyde-induced DNA damage, thereby saturation of DNA repair processes.

31 December 2022 in The Kurume Medical Journal
Verified
Journal Article
Open access
PDF file
DNDaiki Nanri
Daiki Nanri
KYKotaro Yuge
Kotaro Yuge
KGKohei Goto
Kohei Goto
TKTakuro Kimura
Takuro Kimura
YYYukako Yae
Yukako Yae
YYYushiro Yamashita
Yushiro Yamashita
Summary: Background: Until recently, the treatment of spinal muscular atrophy (SMA) was limited to symptomatic treatment with no cure. Three innovative drugs, nusinersen, onasemnogene abeparvovec (OA), and risdiplam have been developed to treat SMA. Although the clinical trials for these drugs have demonstrated their efficacy, there is limited information on real world treatment strategies. In this study, we present a case of a male infant with SMA type 1 who underwent OA treatment after nusinersen treatment. Case presentation: At 4 months of age, the patient was diagnosed with SMA type 1. At 6 months of age, nusinersen treatment was initiated. His motor function improved, but the effect was limited; therefore, his parents requested gene replacement therapy. During the preparation for OA treatment, anti-adeno-associated virus 9 (AAV9) antibody tests repeatedly showed non-specific reactions, which delayed initiation of treatment. The patient was put on ventilator management after he caught a common cold. During this management, the anti-AAV9 antibody test results were negative. Furthermore, the patient showed increased transaminase levels just before OA treatment; however, since these gradually decreased without signs of liver failure, we started OA treatment at 13 months of age. Four months later, the patient began to sit without support and was weaned from non-invasive positive pressure ventilation, although nasogastric tube feeding remained partially necessary. Conclusion: We believe that the management of unstable SMA type 1 symptoms, anti-AAV9 antibody testing, and changes in transaminase levels will be helpful for other patients with SMA who require treatment.

1 June 2020 in Brain and Development
Verified
Journal Article
Closed access
GSGo Shimomura
Go Shimomura
SNShinichiro Nagamitsu
Shinichiro Nagamitsu
MSMasao Suda
Masao Suda
RIRyuta Ishii
Ryuta Ishii
KYKotaro Yuge
Kotaro Yuge
YYYushiro Yamashita
Yushiro Yamashita

2 May 2025 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
NNNaoto Nishimura
Naoto Nishimura
TMTakeshi Mizuguchi
Takeshi Mizuguchi
KHKeisuke Hamada
Keisuke Hamada
KYKotaro Yuge
Kotaro Yuge
MSMasamune Sakamoto
Masamune Sakamoto
NMNaomichi Matsumoto
Naomichi Matsumoto

Verified
Journal Article
Open access
PDF file
KYKunio Yui
Kunio Yui
George ImatakaGeorge Imataka
George Imataka
KYKotaro Yuge
Kotaro Yuge
HSHitomi Sasaki
Hitomi Sasaki
Tadashi ShiohamaTadashi Shiohama
Tadashi Shiohama
HTHidehisa Tachiki
Hidehisa Tachiki
Mutations in TSC1 or TSC2 in axons induce tuberous sclerosis complex. Neurological manifestations mainly include epilepsy and autism spectrum disorder (ASD). ASD is the presenting symptom (25–50% of patients). ASD was observed at significantly higher frequencies in participants with TSC2 than those with TSC1 mutations. The occurrence of TSC2 mutations is about 50% larger than TSC1. Therefore, ASD may develop due to TSC2 deficiency. TSC2 regulates microRNA biogenesis and Microprocessor activity via GSK3β. Of reference, everolimus has the best treatment target because of the higher potency of interactions with mTORC2 rather than rapamycin. Mutations in the TSC1 and TSC2 genes result in the constitutive hyperactivation of the mammalian target of the rapamycin (mTOR) pathway, contributing to the growth of benign tumors or hamartomas in various organs. TSC2 mutations were associated with a more severe phenotypic spectrum than TSC1 mutations because of the inhibition of the mTOR cascade. There are few studies on the peptide analysis of this disorder in relation to everolimus. Only one study reported that, in ten plasma samples, pre-melanosome protein (PMEL) and S-adenosylmethionine (SAM) were significantly changed as diagnostic prognostic effects. Our study on peptide analysis in Protosera Inc (Osaka, Japan) revealed that three peptides that were related to inflammation in two patients with tuberous sclerosis, who showed a 30% decrease in ASD symptoms following everolimus treatment. TSC2 mutations were associated with a more severe phenotypic spectrum due to the inhibition of the mTOR cascade. PMEL and SAM were significantly changed as diagnostic effects.

8 November 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YKYukie Kawahara
Yukie Kawahara
YOYoshinori N. Ohnishi
Yoshinori N. Ohnishi
TTTomoyuki Takahashi
Tomoyuki Takahashi
YKYuki Kishikawa
Yuki Kishikawa
MKMahomi Kuroiwa
Mahomi Kuroiwa
ANAkinori Nishi
Akinori Nishi